JP6712677B2 - 痛みの緩和及び繊維芽細胞の増殖・分化を抑制するための医薬組成物ならびにその製造方法 - Google Patents
痛みの緩和及び繊維芽細胞の増殖・分化を抑制するための医薬組成物ならびにその製造方法 Download PDFInfo
- Publication number
- JP6712677B2 JP6712677B2 JP2019513721A JP2019513721A JP6712677B2 JP 6712677 B2 JP6712677 B2 JP 6712677B2 JP 2019513721 A JP2019513721 A JP 2019513721A JP 2019513721 A JP2019513721 A JP 2019513721A JP 6712677 B2 JP6712677 B2 JP 6712677B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- extraction
- producing
- carbide
- pine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 21
- 230000004069 differentiation Effects 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title claims 10
- 210000002950 fibroblast Anatomy 0.000 title description 7
- 230000035755 proliferation Effects 0.000 title description 6
- 238000000605 extraction Methods 0.000 claims description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 44
- 239000002904 solvent Substances 0.000 claims description 39
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 35
- 235000011613 Pinus brutia Nutrition 0.000 claims description 35
- 241000018646 Pinus brutia Species 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 26
- 239000003610 charcoal Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 238000002137 ultrasound extraction Methods 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000030248 negative regulation of fibroblast proliferation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- BLZVCIGGICSWIG-UHFFFAOYSA-N 2-aminoethoxydiphenylborane Chemical compound C=1C=CC=CC=1B(OCCN)C1=CC=CC=C1 BLZVCIGGICSWIG-UHFFFAOYSA-N 0.000 description 5
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000003563 TRPV Human genes 0.000 description 3
- 108060008564 TRPV Proteins 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- 208000009043 Chemical Burns Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010063562 Radiation skin injury Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229940122575 TRPV agonist Drugs 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000012632 extractable Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000000396 iron Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000006941 response to substance Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- -1 troches Substances 0.000 description 1
- 239000000105 vanilloid receptor agonist Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/13—Burn treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
[1.分野]
[2.関連技術の説明]
[技術的解決手段]
前記及び他の内容並びに本発明の効果は、添付図面を参照して好ましい実施形態で詳細に説明されることによってより明らかになるであろう。
[実施例1]
松かさ炭化物抽出物の調製および式1の化合物の単離
[実施例2]
抽出条件による松かさ炭化物抽出物の比較
抽出方法:還流抽出/超音波抽出
使用した抽出溶媒:メタノール、エタノールおよび水
抽出溶媒の組成:30%、50%、70%および100%
抽出溶媒の量:30mlおよび100ml
抽出時間:10、30、60、90および120分
−抽出方法による比較
[実験実施例1]
式1の化合物の活性アッセイ
[実験実施例1−1]
疼痛緩和効力の評価
線維芽細胞増殖の抑制効力の評価
Claims (6)
- 有効成分として、式1:
式1の化合物を含む松かさ炭化物抽出物を含む、熱傷の副作用として知られる痛みの緩和及び繊維芽細胞の増殖・分化の抑制のために使用される医薬組成物。 - 請求項1に記載の医薬組成物の製造方法であって、
前記松かさ炭化物抽出物が、水、1〜4個の炭素原子を有する低級アルコール、アセトン、酢酸エチル、クロロホルム、またはこれらの混合溶媒を松かさ炭化物に添加することによって調製される、医薬組成物の製造方法。 - 請求項1に記載の医薬組成物の製造方法であって、
前記松かさ炭化物抽出物が、水、1〜4個の炭素原子を有する低級アルコール、またはこれらの混合溶媒を松かさ炭化物に添加することによって調製される、医薬組成物の製造方法。 - 請求項1に記載の医薬組成物の製造方法であって、
前記松かさ炭化物抽出物が、100%メタノールを松かさ炭化物に添加することによって調製される、医薬組成物の製造方法。 - 請求項1に記載の医薬組成物の製造方法であって、
前記松かさ炭化物抽出物が、松かさ炭化物に抽出溶媒を1:1〜1:5(w/v)の比で添加することによって調製される、医薬組成物の製造方法。 - 請求項1に記載の医薬組成物の製造方法であって、
前記松かさ炭化物抽出物が、松かさ炭化物について超音波抽出または還流抽出を行うことによって得られる、医薬組成物の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0167811 | 2016-12-09 | ||
KR1020160167811A KR101811545B1 (ko) | 2016-12-09 | 2016-12-09 | 화상 손상의 치료 또는 예방용 약학 조성물 |
PCT/KR2017/002372 WO2018105817A1 (ko) | 2016-12-09 | 2017-03-06 | 화상 손상의 치료 또는 예방용 약학 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019516801A JP2019516801A (ja) | 2019-06-20 |
JP6712677B2 true JP6712677B2 (ja) | 2020-06-24 |
Family
ID=60936042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019513721A Active JP6712677B2 (ja) | 2016-12-09 | 2017-03-06 | 痛みの緩和及び繊維芽細胞の増殖・分化を抑制するための医薬組成物ならびにその製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190151266A1 (ja) |
JP (1) | JP6712677B2 (ja) |
KR (1) | KR101811545B1 (ja) |
CN (1) | CN109069458B (ja) |
WO (1) | WO2018105817A1 (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248696A (en) | 1991-04-18 | 1993-09-28 | World Research Institute For Science And Technology, Inc. | Composition and method for treating tumors |
KR100494348B1 (ko) * | 2002-07-23 | 2005-06-10 | 남종현 | 화상치료제 및 그 제조방법 |
WO2005084141A2 (en) * | 2004-03-03 | 2005-09-15 | Korea Research Institute Of Bioscience And Biotechnology | Novel abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease |
KR100575253B1 (ko) | 2004-11-04 | 2006-05-02 | 한국생명공학연구원 | 신규 아비에탄 디터페노이드계 화합물 및 이를유효성분으로 함유하는 심장순환계 질환의 예방 및 치료용조성물 |
JP2005306791A (ja) | 2004-04-22 | 2005-11-04 | Arakawa Chem Ind Co Ltd | アビエタンキノン化合物の製造方法 |
US20140363530A1 (en) * | 2012-05-31 | 2014-12-11 | Gueulri | Composition comprising the extract of pine tree leaf or the compounds isolated therefrom for the prevention and treatment of cancer disease by inhibiting hpv virus and the uses thereby |
KR101811544B1 (ko) * | 2016-12-09 | 2017-12-21 | 남종현 | 통증 억제용 조성물 |
-
2016
- 2016-12-09 KR KR1020160167811A patent/KR101811545B1/ko active IP Right Grant
-
2017
- 2017-03-06 US US16/095,356 patent/US20190151266A1/en not_active Abandoned
- 2017-03-06 JP JP2019513721A patent/JP6712677B2/ja active Active
- 2017-03-06 WO PCT/KR2017/002372 patent/WO2018105817A1/ko active Application Filing
- 2017-03-06 CN CN201780024776.9A patent/CN109069458B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019516801A (ja) | 2019-06-20 |
CN109069458B (zh) | 2020-11-10 |
WO2018105817A1 (ko) | 2018-06-14 |
CN109069458A (zh) | 2018-12-21 |
US20190151266A1 (en) | 2019-05-23 |
WO2018105817A9 (ko) | 2018-12-13 |
KR101811545B1 (ko) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7054691B2 (ja) | 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用 | |
Shin et al. | Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease | |
JP2010501639A (ja) | 炎症性疾患の新規治療方法 | |
KR20070100686A (ko) | 개선된 ghb 조성물 | |
JP6712677B2 (ja) | 痛みの緩和及び繊維芽細胞の増殖・分化を抑制するための医薬組成物ならびにその製造方法 | |
KR20080011280A (ko) | 피부과학적 질병의 치료를 위한 피부과학적 조성물 및 염 | |
JP6712676B2 (ja) | 疼痛緩和組成物およびその製造方法 | |
WO2017025989A1 (en) | Method of wound healing | |
US6296878B1 (en) | Tortoise oil, turtle oil, compositions containing them, their preparation processes and uses | |
KR20090048290A (ko) | 캡시에이트 또는 디하이드로캡시에이트의 신규한 용도 | |
NZ570803A (en) | Autoimmune conditions and NADPH oxidase defects | |
JP2023521974A (ja) | メリッサ・オフィシナリス葉の分画抽出物及びそれを含む新規の医薬組成物。 | |
KR101558701B1 (ko) | 아테미신산, 이의 유도체 또는 이들의 화장학적 또는 약학적으로 허용가능한 염을 포함하는 피지 억제용, 및/또는 여드름 피부질환의 예방 또는 개선용 조성물 | |
JP6073136B2 (ja) | 抗炎症化合物 | |
TW201632182A (zh) | 治療皮膚之腫瘤及癌前病理的雷公藤內酯及其衍生物 | |
TWI816842B (zh) | 用於肝病治療或預防的化合物 | |
JPH08208498A (ja) | 皮膚外用剤組成物 | |
WO2013001490A1 (en) | Novel anti-inflammatory dihydrochalcone derivatives and use thereof | |
DE102012103717A1 (de) | Arzneimittel zur Behandlung von Tumorerkrankungen | |
KR20220096097A (ko) | 리놀레산 및 바닐린산을 유효성분으로 함유하는 미세먼지에 의한 탈모완화 화장료 조성물 | |
KR100576519B1 (ko) | 리그난계열 화합물 및 이들의 약학적 용도 | |
BG3739U1 (bg) | Състав на противовъзпалителна таблетка | |
WO2013118077A1 (en) | 2 - hydroxythymol diacetate and use thereof | |
KR20200125047A (ko) | 항염 활성을 갖는 플라보노이드 화합물 및 이를 유효성분으로 포함하는 염증 개선용 조성물 | |
DE3601195A1 (de) | Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200512 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200601 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6712677 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |